News tagged with lapatinib
Related topics: breast cancer
Lapatinib
Lapatinib (INN), used in the form of lapatinib ditosylate, (USAN) (Tykerb/Tyverb, GSK) is an orally active drug for breast cancer and other solid tumours. It is a dual tyrosine kinase inhibitor which interrupts the HER2 growth receptor pathway. It is used in combination therapy for HER2-positive breast cancer. It has been approved as front-line therapy in triple positive breast cancer and as an adjuvant therapy when patients have progressed on Herceptin.
This text uses material from Wikipedia and is available under the GNU Free Documentation License.
Researchers describe how breast cancer cells acquire drug resistance
A seven-year quest to understand how breast cancer cells resist treatment with the targeted therapy lapatinib has revealed a previously unknown molecular network that regulates cell death. The discovery provides new avenues ...
Cancer
May 07, 2013 |
5 / 5 (4) |
0
|
Study suggests patients with lung cancer who carry specific HER2 mutations may benefit from certain anti-HER2 treatments
New results from a retrospective study conducted in Europe suggest that anti-HER2 treatments, like the widely used breast cancer agent trastuzumab (Herceptin), have anti-cancer effects in a small subset of patients with advanced ...
Cancer
Apr 22, 2013 |
not rated yet |
0
Biomarker analysis identified women most likely to benefit from T-DM1
For women with metastatic, HER2-positive breast cancer, the amount of HER2 on their tumor might determine how much they benefit from a drug called trastuzumab emtansine (T-DM1), according to data from a subanalysis of the ...
Cancer
Apr 07, 2013 |
not rated yet |
0
Drug combination shrinks secondary brain tumours in breast cancer without substantial side effects of radiotherapy
The sizeable and increasing proportion of women with advanced breast cancer whose disease has spread to the brain could be effectively treated systemically with a combination of two drugs, sparing them the debilitating neurological ...
Cancer
Nov 01, 2012 |
5 / 5 (1) |
0
Are too few women being offered breast-conserving treatment?
Two new studies presented at the ESMO 2012 Congress in Vienna, Austria show how improvements in breast cancer treatments are making it possible for more women to conserve their breasts following therapy, but raise concerns ...
Cancer
Sep 30, 2012 |
not rated yet |
0
Combination treatment with lapatinib and pazopanib doesn't improve outcomes for patients with IBC
Inflammatory breast cancer is a very aggressive type of cancer associated with early metastasis and poor survival rates, and the prognosis is even worse for patients with tumors expressing the ErbB2 receptor. The ErbB2-inhibiting ...
Cancer
Jun 01, 2012 |
not rated yet |
0
Team reveals novel way to treat drug-resistant brain tumor cells
New research from the University of Wisconsin-Madison explains why the incurable brain cancer, glioblastoma multiforme (GBM), is highly resistant to current chemotherapies.
Cancer
Jun 01, 2012 |
4.5 / 5 (2) |
0
|
Studies help clarify the role of lapatinib and trastuzumab in treating HER2 positive breast cancer
In patients with HER2-positive breast cancer, Tykerb (lapatinib) has been used both in combination with herceptin (trastuzumab) and as an alternative single-agent therapy for pre-surgery (neo-adjuvant) chemotherapy treatment. ...
Cancer
Jan 16, 2012 |
5 / 5 (2) |
0
|
Drug boosts survival when breast cancer spreads to brain
Treatment with lapatinib could extend survival in women with Her2-positive breast cancer that has spread to the brain, according to research published today in the British Journal of Cancer.
Cancer
Nov 30, 2011 |
not rated yet |
0
Gene therapy kills breast cancer stem cells, boosts chemotherapy
Gene therapy delivered directly to a particularly stubborn type of breast cancer cell causes the cells to self-destruct, lowers chance of recurrence and helps increase the effectiveness of some types of chemotherapy, researchers ...
Cancer
Sep 12, 2011 |
5 / 5 (2) |
0
|
